succinic acid has been researched along with Coronary Disease in 5 studies
Succinic Acid: A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851)
succinic acid : An alpha,omega-dicarboxylic acid resulting from the formal oxidation of each of the terminal methyl groups of butane to the corresponding carboxy group. It is an intermediate metabolite in the citric acid cycle.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| SUBERVIOLA, J | 1 |
| GALANTE, GD | 1 |
| CINTAS, JA | 1 |
| Bittl, JA | 1 |
| Shine, KI | 1 |
| Muscari, C | 1 |
| Turinetto, B | 1 |
| Colì, G | 1 |
| Galeazzi, M | 1 |
| Cattabriga, I | 1 |
| Finelli, C | 1 |
| Biagetti, L | 1 |
| Guarnieri, C | 1 |
| Caldarera, CM | 1 |
| Ueta, H | 1 |
| Ogura, R | 1 |
| Sugiyama, M | 1 |
| Kagiyama, A | 1 |
| Shin, G | 1 |
| Onishchenko, NA | 1 |
| Lubiako, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
5 other studies available for succinic acid and Coronary Disease
| Article | Year |
|---|---|
[The action of succinic acid in chronic coronary insufficiency].
Topics: Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Disease; Diuretics; Humans; Succinates; Succini | 1953 |
Protection of ischemic rabbit myocardium by glutamic acid.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Coronary Disease; Coronary Vessels; Glutamates; Glu | 1983 |
Changes in myocardial mitochondrial respiration after ligation of the coronary artery in pigs.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Fractionation; Coronary Disease; Corona | 1990 |
O2-. spin trapping on cardiac submitochondrial particles isolated from ischemic and non-ischemic myocardium.
Topics: Animals; Cattle; Coronary Disease; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Free Radic | 1990 |
[Anti-ischemic protection of the myocardium by cardioplegic solutions].
Topics: Animals; Coronary Disease; Dogs; Heart Arrest, Induced; Magnesium; Magnesium Chloride; Potassium Chl | 1985 |